"Scientists at the National Institutes of Health report they have discovered in mouse studies that a small molecule released in the spinal cord triggers a process that is later experienced in the brain as the sensation of itch.
- Patient Information:
Details with Side Effects
Mechanism of Action
The mechanism of action of ketoconazole in the treatment of seborrheic dermatitis is not known.
The pharmacodynamics of Extina (ketoconazole foam, 2%) Foam has not been established.
In a bioavailability study, 12 subjects with moderate to severe seborrheic dermatitis applied 3 g of Extina (ketoconazole foam, 2%) Foam twice daily for 4 weeks. Circulating plasma levels of ketoconazole were < 6 ng/mL for a majority of subjects (75%), with a maximum level of 11 ng/mL observed in one subject.
Ketoconazole is an antifungal agent which inhibits the in vitro synthesis of ergosterol, a key sterol in the cell membrane of Malassezia furfur. The clinical significance of antifungal activity in the treatment of seborrheic dermatitis is not known.
The safety and efficacy of Extina (ketoconazole foam, 2%) Foam were evaluated in a randomized, double-blind, vehicle-controlled study in subjects 12 years and older with mild to severe seborrheic dermatitis. In the study, 427 subjects received Extina (ketoconazole foam, 2%) Foam and 420 subjects received vehicle foam. Subjects applied Extina (ketoconazole foam, 2%) Foam or vehicle foam twice daily for 4 weeks to affected areas on the face, scalp, and/or chest. The overall disease severity in terms of erythema, scaling, and induration was assessed at Baseline and week 4 on a 5-point Investigator's Static Global Assessment (ISGA) scale. Treatment success was defined as achieving a Week 4 (end of treatment) ISGA score of 0 (clear) or 1 (majority of lesions have individual scores for scaling, erythema, and induration that averages 1 [minimal or faint]) and at least two grades of improvement from baseline. The results are presented in Table 2. The database was not large enough to assess whether there were differences in effects in age, gender, or race subgroups.
Table 2: Efficacy Results
|Number of Subjects
||Extina (ketoconazole foam, 2%) Foam
N = 427
N = 420
|Subjects Achieving Treatment Success||239 (56%)||176 (42%)|
Last reviewed on RxList: 7/9/2007
This monograph has been modified to include the generic and brand name in many instances.
Additional Extina Information
Extina - User Reviews
Extina User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
Find out what women really need.